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Extracellular adenosine (Ado) has been implicated as central signaling molecule during 
conditions of limited oxygen availability (hypoxia), regulating physiologic outcomes as 
diverse as vascular leak, leukocyte activation, and accumulation. Presently, the molecular 
mechanisms that elevate extracellular Ado during hypoxia are unclear. In the present study, 
we pursued the hypothesis that diminished uptake of Ado effectively enhances extracellular 
Ado signaling. Initial studies indicated that the half-life of Ado was increased by as much as 
fivefold after exposure of endothelia to hypoxia. Examination of expressional levels of the 
equilibrative nucleoside transporter (ENT)1 and ENT2 revealed a transcriptionally dependent 
decrease in mRNA, protein, and function in endothelia and epithelia. Examination of the 
ENT1 promoter identified a hypoxia inducible factor 1 (HIF-1)–dependent repression of 
ENT1 during hypoxia. Using in vitro and in vivo models of Ado signaling, we revealed that 
decreased Ado uptake promotes vascular barrier and dampens neutrophil tissue accumulation 
during hypoxia. Moreover, epithelial 
 
Hif1
 
 
 
 mutant animals displayed increased epithelial 
ENT1 expression. Together, these results identify transcriptional repression of ENT as an 
innate mechanism to elevate extracellular Ado during hypoxia.
 
Limited oxygen availability (hypoxia) is central
to the pathogenesis of many cardiovascular,
infectious, and inflammatory diseases. Patho-
physiologic changes related to hypoxia include
changes in tissue permeability, accumulation of
inflammatory cells, and transcriptional induction
of proinflammatory cytokines (1, 2). Recent
studies have also identified hypoxia-elicited
factors that counterregulate such proinflam-
matory circuit, thereby functioning as endoge-
nous antiinflammatories (3). Central to this lat-
ter pathway is extracellular adensoine (Ado),
which through activation of surface-expressed
receptors on a variety of cells, dampens ongoing
inflammation (2, 4–6) and promotes wound
healing (7). At present, the exact metabolic
steps for generation of extracellular Ado in
hypoxia are not well characterized, but likely
involve increased enzymatic phosphohydrolysis
from precursor adenine nucleotides (ATP,
ADP, and AMP). For instance, we recently
demonstrated that hypoxia coordinates both
transcriptional and metabolic control of the
surface ectonucleotidases CD39 and CD73
(8–10), and thereby amplifies extracellular ac-
cumulation of Ado. Additional mechanisms
also exist to amplify Ado signaling during hyp-
oxia, including coordinate changes at the Ado
receptor level. For instance, the vascular endo-
thelial Ado receptor subtype AdoRA
 
2B
 
 is se-
lectively induced by hypoxia and such in-
creases in receptor density are associated with
increased vascular barrier responses to Ado (8).
Once generated into the extracellular milieu,
Ado is rapidly cleared through passive or active
uptake by nucleoside transporters, termed
equilibrative nucleoside transporters (ENTs)
and concentrative nucleoside transporters,
respectively, expressed on a variety of cell types
(11, 12). Recent studies suggest that the pre-
dominant functional nucleoside transporters in
the vascular endothelium are ENT1 and ENT2,
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with a minimal contribution by centrative nucleoside trans-
porters (13), wherein ENT1 and 2 are bidirectional transport-
ers functioning as diffusion-limited channels for transmem-
brane nucleoside flux. Previous studies have suggested that
vascular Ado transport during hypoxia is predominantly in-
ward (14), thereby terminating extracellular Ado signaling.
However, more recent studies show that the expression of
ENT1 may be transcriptionally regulated by hypoxia (15, 16),
thereby functioning to fine tune extracellular levels of Ado.
Therefore, we examined the influence of hypoxia on en-
dothelial and epithelial Ado transport. Results from these
studies revealed that ENT1 and ENT2 gene expression and
function are attenuated by hypoxia, and that this regulatory
circuit maps to hypoxia inducible factor 1 (HIF-1)–mediated
repression of ENT expression. These studies provide new
molecular insight into endogenous mechanisms of tissue
protection during hypoxia.
 
RESULTS
Increased extracellular Ado half-life 
in posthypoxic endothelia
 
Recent studies suggest that hypoxia promotes a cellular phe-
notype that supports high capacity for rapid nucleotide phos-
phohydrolysis and enhanced Ado signaling (8, 9). As an ex-
tension of these studies, we addressed whether mechanisms of
extracellular Ado clearance were different in posthypoxic en-
dothelial cells. Initial studies indicated that hypoxia signifi-
cantly decreased endothelial uptake of exogenous Ado (Fig. 1
a), thereby increasing Ado half-life. Indeed, these studies in-
dicated that human microvascular endothelial cells (HMEC)-1
subjected to hypoxia (pO
 
2
 
 20 torr, 48 h) and examined for
their capacity to transport extracellular Ado (Ado
 
EC
 
, 50 
 
 
 
M
final concentration), had significantly attenuated ability to
transport Ado (Ado
 
EC
 
 19.2 
 
 
 
 0.6 
 
 
 
M at 2 h) compared with
normoxic controls (Ado
 
EC
 
 1.3 
 
 
 
 1.1
 
 
 
M at 2 h, P 
 
  
 
0.01).
Control experiments performed at 4
 
 
 
C or in the presence of
the ENT-inhibitor dipyridamole (10 
 
 
 
M) revealed signifi-
cant attenuation of Ado uptake (Ado
 
EC
 
 40 
 
 
 
 1.6 and 33 
 
 
 
2.1 
 
 
 
M concentrations, respectively; P 
 
  
 
0.001), indicating
that endothelial Ado uptake requires metabolism and depends
on dipyridamole-sensitive carriers. Subsequent studies ad-
dressing the hypoxia time course (Fig. 1 b) and dose response
(Fig. 1 c) revealed a time-dependent (P 
 
  
 
0.01) and dose-
dependent (P 
 
  
 
0.05) decrease in transport of Ado
 
EC
 
.
To confirm that the observed decreases in Ado
 
EC
 
 reflects
transport and to rule out other potential mechanisms of Ado
loss (e.g., metabolism by the ecto-Ado deaminase) (17), we
determined the kinetics of 
 
14
 
C-Ado
 
EC
 
 transmembrane trans-
port (Fig. 1 d). These studies confirmed our studies with na-
tive Ado and revealed that 
 
14
 
C-Ado
 
EC
 
 transport was 63 
 
 
 
 6%
decreased in posthypoxic endothelia relative to normoxia (P 
 
 
 
0.001). In parallel, 
 
14
 
C-Ado
 
EC
 
 transport at 4
 
 
 
C or in the pres-
ence of dipyridamole revealed significant attenuation of endo-
thelial uptake (P 
 
  
 
0.001). Together, these data suggest an ad-
ditional mechanism to elevate Ado
 
EC
 
 involves diminished
active uptake through endothelial membrane transporters.
 
Hypoxia rapidly represses expression of endothelial 
and epithelial ENT1 and ENT2 mRNA
 
Prompted by these results, recent findings that ENT1/2 pre-
dominate in the vascular endothelium (13) and that hypoxia
down-regulates dipyridamole-sensitive Ado transporters (15,
16), we examined the influence of hypoxia on expression of
ENT1 and ENT2 mRNA. Initial insight gained by microar-
ray analysis revealed an 85 
 
 
 
 5 and 78 
 
 
 
 4% inhibition of
ENT1 and ENT2 mRNA expression, respectively (18 h hy-
poxia, pO
 
2
 
 20 torr). As shown in Fig. 2 a, real-time PCR
analysis confirmed our microarray results and revealed a
time-dependent loss of both ENT1 (95 
 
 
 
 8% loss at 24 h,
P 
 
  
 
0.01) and ENT2 (81 
 
 
 
 7% loss at 24 h of hypoxia, P 
 
 
Figure 1. Influence of hypoxia on endothelial Ado uptake. (a) HMEC-1 
cells were subjected to normoxia (N, pO2 147 torr, 48 h) or hypoxia (H, pO2 
20 torr, 48 h) and Ado transport (50  M at t   0) was quantified. Control 
experiments were performed in the presence of dipyridamole (10  M) 
(D), or at 4 C (cold). (b) HMEC-1 were exposed to indicated periods to 
hypoxia (pO2 20 torr) and Ado transport (50  M at t   0) was quantified. 
(c) Measurement of Ado half life in the supernatant of HMEC-1 cells 
cultured under hypoxic conditions with indicated oxygen concentration 
(*P   0.01, different from normoxia). (d) To measure intracellular Ado 
uptake, HMEC-1 cells were subjected to normoxia (N) or hypoxia (H) over 
48 h, and were exposed to 50  M Ado containing 10 nCi of 8-14C-Ado. 
Cells were washed and lysed after indicated time periods, and radioactivity 
was measured. 
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0.01). In addition, we found that expression levels of ENT1
mRNA in HMEC-1 were approximately fourfold higher
compared with ENT2 mRNA.
Similar results of ENT1 and ENT2 repression were
found when human saphenous vein tissues were subjected to
hypoxia, indicating that such findings are not limited to cul-
tured endothelium (Fig. 2 b, P 
 
  
 
0.001). Additionally,
ENT1 and ENT2 expression were decreased in T84 cells and
intestinal epithelial cell line (Fig. 2 c, P 
 
  
 
0.001), further sug-
gesting that these findings are not limited to endothelial cells.
Figure 2. Repression of ENT1 and ENT2 mRNA and protein expression 
by hypoxia. (a) Confluent HMEC-1 monolayers were exposed to normoxia 
or hypoxia for indicated time periods. Total RNA was isolated, and ENT1/
ENT2 mRNA levels were determined by real-time PCR. Data were calculated 
relative to  -actin and expressed as fold change relative to normoxia   SD. 
Results are derived from three experiments (*P   0.01, different from 
normoxia and ENT2; #P   0.01, different from normoxia). (b) Human 
saphenous vein was obtained from patients undergoing coronary bypass 
surgery and exposed ex vivo to normoxia (24 h) or hypoxia (2, 8, or 24 h). 
Real-time PCR was used to define ENT1 and ENT2 mRNA levels. Data were 
calculated relative to  -actin and are expressed as fold change compared 
with normoxia   SD. Results are derived from three experiments (*P   0.01, 
different from normoxia and ENT2; #P   0.01, different from normoxia). 
(c) Confluent T84 epithelial cell monolayers were exposed to normoxia (24 h) 
or hypoxia for indicated time periods. Total RNA was isolated and ENT1/ENT2 
mRNA levels were determined by real-time PCR. Results are derived from 
three experiments (*P   0.01, different from normoxia and ENT2; #P   0.01 
different from normoxia). (d) HMEC-1 cells were grown to confluence and 
exposed to indicated periods of hypoxia. Shown here is a representative 
Western blot of ENT-1. The same blot was probed for  -actin expression 
as a control for protein loading.
Figure 3. Influence of siRNA knockdown of ENT1 and ENT2 on 
endothelial Ado uptake. Real-time PCR was used to confirm down-
regulation of ENT1 and ENT2 mRNA by siRNA loading in cultured endothelial 
cells. HMEC-1 cells were loaded with siRNA for ENT1 (a), ENT2 (b), control 
siRNA (c), or siRNA specific for CD73 (d and e). Data were calculated relative 
to  -actin and are expressed as fold decrease over control   SD at each 
indicated siRNA concentration. Results are derived from three experiments 
(*P   0.01, different from control). (d) siRNA knockdown with siRNA 
directed against CD73 did not influence expression of ENT1 or ENT2. 
(e) Repression of CD73 dose response. (f) Measurement of intracellular 
Ado uptake after siRNA loading. HMEC-1 cells were transfected with 
200-nM concentrations of siRNA for ENT1, ENT2, ENT1 and ENT2, or control 
siRNA for 48 h. Intracellular Ado uptake was measured by exposing cell to 
50  M Ado containing 10 nCi of 8-14C-Ado. Cells were lysed after 30 min 
and radioactivity was measured (*P   0.01, different from control). 
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We extended these mRNA findings to examine ENT1
protein expression in cultured HMEC-1. As shown in Fig. 2
d, Western blot analysis of lysates derived from HMEC-1
subjected to hypoxia (pO
 
2
 
 20 torr for 6–36 h) revealed a dra-
matic loss of ENT1 with increasing time in hypoxia. Protein
repression was maximal at 36 h time periods of hypoxia (no
additional loss was evident at 48 h).
 
ENT1 repression mediates attenuated endothelial Ado 
uptake during hypoxia
 
We next determined whether inhibition of ENT gene expres-
sion was required for the observed functional differences in
Ado uptake between posthypoxic and postnormoxic endothe-
lia. Here, we used siRNA-mediated repression in HMEC-1 of
ENT1 or ENT2 for gaining insight into relative contributions
of these individual gene products on Ado
 
EC
 
 transport. As a first
step, we generated siRNA double-stranded oligoribonucle-
otides specific for ENT1 and ENT2 and profiled ENT expres-
sion by PCR (Fig. 3, a and b). As control siRNA, we used a
single-stranded forward oligoribonucleotide, which did not in-
fluence ENT1 or ENT2 mRNA expression (Fig. 3 c), sug-
gesting that the aforementioned findings of decreased ENT1
or ENT2 expression (Fig. 3, a and b) were specific for targeted
gene knock-down by the chosen siRNA molecules. As ad-
ditional control, we used double-stranded siRNA directed
against the 5
 
 
 
-ectonucleotidase (CD73), an endothelial surface
enzyme that facilitates conversion of Ado monophosphate to
Ado. As shown in Fig. 3 (d and e), siRNA repression of CD73
did not influence expressional levels of ENT1 or ENT2. After
showing that siRNA-mediated repression of ENT1 and ENT2
was specific and highly efficient using the aforementioned con-
ditions (81 
 
 
 
 8% inhibition of ENT1 mRNA expression, P 
 
 
 
0.01, and 79 
 
 
 
 10% inhibition of ENT2, P 
 
  
 
0.01), we mea-
sured endothelial Ado uptake using 
 
14
 
C-Ado. As shown in Fig.
3 f, whereas 
 
14
 
C-Ado uptake was not influenced by siRNA re-
pression with control siRNA (5 
 
 
 
 1% decrease compared with
mock-loaded cells, p-values were not significant) or siRNA
directed against ENT2 (14 
 
 
 
 7% decrease compared with
mock-loaded cells, p-values were not significant), Ado uptake
was decreased after siRNA-mediated repression of ENT1
(76 
 
 
 
 7% decrease compared with mock-loaded cells, P 
 
  
 
0.01)
or simultaneous ENT1 and ENT2 repression (81 
 
 
 
 5% de-
crease compared with mock-loaded cells, P   0.01). Together,
these results implicate ENT1 as the prevailing mechanism for
the observed changes in endothelial Ado.
Decreased endothelial Ado uptake promotes endothelial 
barrier function in vitro
We next determined whether hypoxia-mediated repression
of ENT1 might enhance signaling mediated by AdoEC.
Here, we compared Ado responses of normoxic and post-
hypoxic endothelia using a previously described in vitro model
of endothelial barrier (8, 18). As reported previously (8), we
observed that barrier function (i.e., flux 70-kD FITC-dex-
tran) in response to Ado was enhanced to a greater extent in
posthypoxic HMEC-1 than in normoxic HMEC-1 (Ado
EC50’s of  30  M and  1  M for normoxia and post-
hypoxia, respectively; Fig. 4 a). To define the contribution
of hypoxia-mediated repression of ENT1/2, we repeated
this experiment in the presence of the ENT inhibitor dipy-
ridamole (10  M). As shown in Fig. 4 b, in the presence of
dipyridamole, the dose response to Ado became indistin-
guishable between hypoxia and normoxia (Ado EC50 of
 0.1  M for both), implicating hypoxia-mediated repression
of ENT1/2 in functional Ado responses.
We next defined the contribution of ENT1 or ENT2 to
such changes in Ado-elicited barrier responses of the endo-
thelium. To do this, we used the aforementioned siRNA re-
pression approach. As shown in Fig. 4 c, siRNA repression
Figure 4. Influence of Ado uptake inhibition on endothelial barrier 
function in vitro. (a) Indicated concentrations of Ado were added to the 
apical surface of normoxic (48 h, pO2 147) or posthypoxic (48 h, pO2 20 torr) 
HMEC-1 and permeability to FITC-dextran (70kD) was quantified. Data are 
derived from six monolayers in each condition and expressed as mean   SD 
of percent control flux. *, significant differences from baseline (P   0.05); 
#, differences from baseline and from normoxia (P   0.05). (b) Influence of 
10  M dipyridamole on Ado barrier responses in normoxic and posthypoxic 
endothelia. (c) Influence of ENT1 and ENT2 (d) suppression by siRNA on 
Ado elicited endothelial barrier responses. HMEC-1 cells were loaded with 
ENT1- or ENT2-specific siRNA or control ribonucleotide (200 nM) and, after 
48 h, permeability to 70 kD FITC was measured in the presence of indicated 
Ado concentrations. Data are derived from six monolayers in each condition 
and expressed as mean   SD of percent control flux.JEM VOL. 202, December 5, 2005 1497
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of ENT1 was associated with an increase of Ado elicited bar-
rier responses (P   0.01). In contrast, loss of ENT2 was not
associated with a measurable change in endothelial Ado re-
sponse (Fig. 4 d). These data reveal that inhibition of Ado
uptake, either via hypoxia inhibition of ENT gene expres-
sion, pharmacological intervention, or siRNA repression of
ENT1, represents an adaptive mechanism to elevate extra-
cellular Ado levels, and thereby prolong signaling mediated
by this nucleoside.
HIF-1 –dependent repression of ENT1 promoter
In an attempt to gain specific insight into the molecular
mechanisms of ENT1 repression by hypoxia, we profiled
promoter activity in HMEC-1 transfected with luciferase
promoter constructs expressing varying length 5 -truncations
(225, 282, 344, and 756 bp relative to the major transcrip-
tion start site). Highest basal expression (i.e., normoxia) was
observed in the 756-bp construct (15   2.1-fold over back-
ground) and graded decreases in baseline activity were ob-
served with increasing 5 -truncation (6.8   1.7, 3   1.1,
and 5   0.6-fold over background for 344-, 282-, and 225-
bp truncations, respectively). Comparison of promoter activ-
ity in HMEC-1 exposed to hypoxia or normoxia revealed
that, whereas other constructs were expressed at or near the
level of the normoxia control, expression of the 756-bp frag-
ment was repressed by 59   6% compared with normoxia
controls (Fig. 5 a, P   0.01). Such analysis indicates that the
region spanning  344 to  756 of the ENT1 promoter confers
hypoxia-repressive activity.
In the course of our experiments, we identified two po-
tential HIF binding sites oriented on the antisense strand
of the ENT1 gene promoter (DNA consensus motif 3 -
CCGTG-5  and 3 -CCGTG-5  located at positions from
 653 to  657 and  717 to  721, respectively, relative to
the major transcription start site). Because HIF can mediate
transcriptional induction or repression (19, 20), we deter-
mined if either of these putative HIF-1–binding sites con-
ferred hypoxia repression of ENT1 in HMEC-1. First, we
examined the kinetics of HIF-1  expression in our HMEC-1
cultures. As shown in Fig. 5 b, Western blot analysis of
HIF-1  revealed minimal protein in hypoxia, and time-
dependent induction over a 24-h period of hypoxia. Such
kinetics are consistent with the loss of ENT1 protein during
hypoxia (Fig. 2 d). Second, HIF-1 –binding site mutations
( 657 and  721) were introduced in the 756-bp construct,
and as shown in Fig. 5 c, mutation of the  717 to  721
site, but not the  653 to  657 site, reversed hypoxia re-
pression of this promoter construct, suggesting that this re-
gion of the promoter, at least in part, confers hypoxia repres-
sor activity. Third, we determined whether this region of
the ENT1 promoter binds HIF-1 . For these purposes, we
used chromatin immunoprecipitation (ChIP) to analyze
HIF-1  binding in live cells. As shown in Fig. 5 d, ChIP
analysis of nuclei derived from HMEC-1 cells revealed a
prominent band of 192 bp in hypoxic but not normoxic
samples. No bands were evident in control IgG immunopre-
Figure 5. Influence of hypoxia on ENT1 promoter activity. (a) Indicated 
serial truncations of the ENT1 promoter reporter were transfected in HMEC-1 
cells along with Renilla reporter plasmids and assayed for firefly and Renilla 
luciferase activity, respectively, after exposure to hypoxia for 48 h. Results 
depict the fold change in relative luminescence in hypoxia relative to normoxic 
controls. An HRE plasmid containing four tandem hypoxia-responsive 
elements is shown as a positive control (HRE). Data shown are a pooled 
experiments from n   4 and are normalized for background vector (empty 
PGL3) and Renilla luciferase to control for transfection efficiency, and 
presented as mean   SD, where * indicates significance between individual 
plasmids and empty PGL3 plasmid (P   0.025) and # indicates significance 
between HRE and ENT1-756 (P   0.025). (b) HMEC-1 cells were grown to 
confluence and exposed to indicated periods of hypoxia. Nuclear lysates were 
isolated and resolved by SDS-PAGE. Shown here is a representative Western 
blot of HIF-1  under these conditions. The same blot was probed for  -actin 
expression as control for protein loading. (c) The putative HIF sites located at 
 721 and  657 bp were mutated in the  756 construct by site-directed 
mutagenesis. The resulting constructs (ENT1 721) and (ENT1 657) was 
cotransfected along with Renilla luciferase vector into HMEC1 cells followed 
by 48 h of hypoxia. An HRE plasmid containing four tandem hypoxia-
responsive elements is shown as a hypoxia positive control. Data shown are 
pooled from n   4 and are normalized for background vector (empty PGL3) 
and Renilla luciferase to control for transfection efficiency and presented as 
mean   SD, where * indicates significance between ENT1-756 and ENT1 721 
(P   0.025) and # indicates significance between HRE and ENT1-756 
(P   0.025). (d) Chromatin immunoprecipitation was used to examine HIF-1  
binding to the ENT1 promoter in normoxic and hypoxic HMEC-1. Reaction 
controls included PCR performed using whole HMEC-1 genomic DNA (input) 
and samples precipitated by protein G sepharose beads alone (Cntl IP).HIF-1–DEPENDENT REPRESSION OF ENT | Eltzschig et al. 1498
cipitates, and input samples (preimmunoprecipitation) re-
vealed the predictable 192-bp band under conditions of both
hypoxia and normoxia. Such results indicate that hypoxia in-
duces HIF-1  binding to the distal 192-bp region of the
ENT1 promoter. Together, these results provide strong evi-
dence for a functional hypoxia repressor activity, mediated
by HIF-1, in the distal 5 -region the ENT1 promoter.
Role of HIF-1  in epithelial ENT1 regulation
We next pursued the finding that epithelial ENT expression,
like that in endothelia, is repressed by hypoxia (Fig. 2 c).
To probe the role of HIF-1  in an epithelial model, we
generated a T84 cell line expressing oxygen-stable HIF-1 
(T84 ODD) (21) via lentiviral transduction (Fig. 6). As
shown in Fig. 6 a, using this lentiviral vector-expressing GFP,
 90% of T84 cells were stably transduced by this method.
Analysis of the T84 ODD by Western blot (Fig. 6 b) and by
hypoxia-responsive element (HRE) luciferase (Fig. 6 c) re-
vealed increased HIF function and activity in both normoxia
and hypoxia, releative to the control T84-GFP cell line. The
further increase of HIF function and activity with hypoxia
most likely reflects the presence of oxygen-stable and oxygen-
unstable HIF-1 .
Using the T84 ODD cell line, we addressed whether
ENT1 expression was differentially regulated. As shown in
Fig. 7 a, ENT1 mRNA expression in normoxia was de-
creased by  80% in the T84 ODD relative to the control
T84-GFP cell line (P   0.01). Likewise, enhanced repres-
sion of ENT1 was observed in T84 ODD compared with
control T84-GFP cells at 6, 12, and 24 h of hypoxia (P  
0.025 for each). Additionally, comparison of promoter activ-
ity in T84 ODD and T84-GFP cell lines exposed to hyp-
oxia or normoxia revealed enhanced repression of the 756-
Figure 6. Characterization of epithelial cell line expressing oxygen-
stable HIF-1 . (a) Imaging of T84 cells stably transduced with a control 
lentivirus encoding GFP. For comparison, the phase contrast image is also 
shown. (b) Cells were transduced with control GFP lentivirus (T84-GFP) or 
 ODD lentivirus (T84- ODD), exposed to normoxia or hypoxia (6 h), and 
nuclear HIF-1  expression was examined by Western blot ( -actin controls 
are also shown). (c) T84-GFP and T84- ODD cells were transiently transfected 
with the HIF reporter HRE-luciferase plasmid, and exposed to hypoxia or 
normoxia (24 h). Relative HIF activity was assessed by luciferase relative to 
empty vector (pGL3). Results are presented as fold above PGL3 background 
(relative to control plasmids expressing Renilla in each condition).
Figure 7. Functional regulation of ENT1 expression in epithelial 
cells expressing oxygen-stable HIF-1 . (a) T84-GFP and T84- ODD cells 
were exposed to indicated periods of hypoxia and examined for ENT1 
expression by real-time PCR. Data were calculated relative to  -actin and 
are expressed as relative change   SD at each indicated time. Results are 
derived from three experiments in each condition (*P   0.01, different from 
normoxia and ENT2; #P   0.01, different from normoxia). (b) T84-GFP and 
T84- ODD cells were transiently transfected with the wild-type ENT promoter 
construct (ENT1-756) and exposed to hypoxia or normoxia (24 h). Relative 
activity was assessed by luciferase relative to empty vector (pGL3). Results 
are presented as relative change in activity above PGL3 background (relative 
to control plasmids expressing Renilla in each condition).JEM VOL. 202, December 5, 2005 1499
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bp fragment in cells expressing oxygen-stable HIF-1  (Fig. 7
b). Such findings support the hypothesis that ENT1 repression
is proportional to HIF-1  activity.
In vivo analysis of ENT function on the vasculature
As proof of principle for these in vitro and ex vivo findings
of hypoxia-induced ENT repression, we extended these
findings to an in vivo model. We and others have shown
that hypoxia promotes vascular leak and tissue PMN accu-
mulation in vivo (1, 8, 10, 22–24). Thus, we pursued phar-
macological inhibition of Ado uptake in a previously described
murine hypoxia model (8, 10, 22).
As first step, we administered the ENT inhibitor dipy-
ridamole (10 mg/kg i.p. and 10 mg/kg s.c.) or PBS and sub-
jected animals to either normoxia or hypoxia (8% O2 and 92%
N2) for 4 h. Plasma levels of dipyridamole (determined by
HPLC) ranged between 25- and 110-nm concentrations dur-
ing the course of the experiment (Fig. 8 a), consistent with
previous dosing studies with dipyridamole and dipyridamole
analogues (25). In previous in vivo hypoxia experiments,
we observed the lungs as particularly prone to developing
hypoxia-induced vascular leak and pulmonary edema (10).
Therefore, we assessed pulmonary edema by determining
lung water content (wet/dry ratio). As shown in Fig. 8 b, hyp-
oxia increased lung water content from 3.81  0.42 mg/mg
dry tissue to 5.83   0.54 (P   0.05) in PBS treated mice. In
contrast, lung water was decreased in dipyridamole-treated
animals by 16   2% under normoxic conditions, and by 21  
3% (P   0.025) under hypoxic conditions (P   0.05). These
results suggest that pharmacological inhibition of Ado uptake
is associated with a decrease in lung water.
To assess vascular barrier function of other organs, we
administered the albumin marker Evan’s blue before hyp-
oxia. Comparative analysis in normoxia revealed decreased
Evan’s blue concentrations in all examined organs (colon,
lung, liver, and kidney) of dipyridamole-treated mice com-
pared with PBS controls. Comparison of vascular perme-
ability in dipyridamole or PBS-treated mice subjected to
normobaric hypoxia (8% O2, 92% N2 for 4 h) revealed sig-
nificantly increased vascular leak in all animals, however to
smaller degree in dipyridamole-treated animals (P   0.05 for
all organs; Fig. 8 c). These findings support our hypothesis
that decreased Ado uptake by the endothelium is a protec-
tive cellular strategy to dampen changes in vascular barrier
function, both at baseline and during hypoxia-induced
barrier dysfunction.
We next examined whether a reduction of Ado uptake
at the vascular surface may also function as antiinflammatory
response during hypoxia, particularly given the antiinflam-
matory properties of Ado (4, 6). To test this hypothesis, we
screened multiple mucosal organs (colon, lung, liver, and
kidney) for PMN accumulation after administration of dipy-
ridamole (Fig. 8 d). This analysis revealed decreased myelo-
peroxidase (MPO) activity in all organs of dipyridamole-
treated animals. Consistent with previous studies (26), MPO
Figure 8. Influence of dipyridamole on pulmonary edema, vascular 
permeability, and PMN accumulation in vivo. BL/6/129 mice were 
injected with dipyridamole (10 mg/kg i.p. and 10 mg/kg s.c.) or with PBS, 
and exposed to normoxia (room air) or normobaric hypoxia (8% O2 and 
92% N2) for 4 h. (a) Dipyridamole plasma levels were measured by HPLC 
and compared with standards of known dipyridamole concentration. 
Mean plasma dipyridamole concentrations were 33.7   10.2 nM with no 
differences between treatment groups (P   0.05). (b) Assessment of 
lung water content in normoxia (black bars) and hypoxia (gray bars) 
after dipyridamole or PBS treatment. Data are expressed as mean   SD 
mg H2O/mg dry tissue, and are pooled from four animals per condition. 
*, difference between hypoxia and normoxia (P   0.025); #, difference 
between dipyridamole treatment and vehicle control (P   0.025). (c) Evan’s 
blue vascular permeability. Animals were killed and indicated organs 
were harvested. Evan’s blue concentrations were quantified as described 
in Materials and methods. Data are expressed as mean   SD Evan’s blue 
OD/50mg wet tissue, and are pooled from four to six animals per 
condition, where * indicates differences between dipyridamole/PBS 
treatment groups (P   0.025) and # indicates differences between 
normoxia/hypoxia exposure (P   0.05). (d) Organ assessment of PMN 
accumulation by MPO measurements in the indicated organs after 4 h 
of normoxia/hypoxia exposure (*P   0.025 compared with PBS, #P   0.025 
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levels were significantly increased after hypoxia exposure in
all animals, however to a much lesser extend in all organs of
dipyridamole-treated animals compared with PBS controls
(P   0.05 for all organs). These in vivo findings support the
hypothesis that Ado uptake via dipyridamole-sensitive carri-
ers is a critical control point in the regulation of PMN accu-
mulation within normoxic and hypoxic tissues and suggest
ENT down-regulation as innate antiinflammatory adaptation.
It is known that the two nucleoside transporters ENT1
and ENT2 differ in their sensitivity to inhibition by the
inosine analogue NBTI (27, 28). NBTI is a highly potent in-
hibitor of ENT1 (IC50  0.4–8 nM), whereas it is only a
moderate inhibitor of ENT2 (IC50  3  M). Based on phar-
macokinetic studies of NBTI in mice, we used an NBTI dose
that would result in estimated plasma levels between 1 and 10
nM (29). To pursue this, we administered NBTI (1 mg/kg
i.p.) or vehicle (DMSO) and subjected animals to either nor-
moxia or normobaric hypoxia. As shown in Fig. 9 a, hypoxia
significantly increased lung water content in vehicle-treated
animals (P   0.05). In contrast, lung water was decreased in
NBTI-treated animals under normoxic or hypoxic condi-
tions. Measurement of vascular barrier function revealed sig-
nificantly increased vascular leak with hypoxia in all animals,
however to a smaller degree in NBTI treated animals (P  
0.05 for all organs; Fig. 9 b). Finally, we also screened multi-
ple mucosal organs for PMN accumulation (Fig. 9 c). Consis-
Figure 9. Influence of S-(4-Nitrobenzyl)-6-thioinosine (NBTI) on 
pulmonary edema, vascular permeability, and PMN accumulation in 
vivo. BL/6/129 mice were administered NBTI (1 mg/kg i.p. in DMSO) or 
vehicle alone, and exposed to normoxia or hypoxia for 4 h. (a) Assessment 
of lung water content in normoxia (black bars) and hypoxia (gray bars) after 
dipyridamole or vehicle treatment. Data are expressed as mean   SD mg 
H2O/mg dry tissue, and are pooled from four animals per condition. 
*, difference between hypoxia and normoxia (P   0.025); #, difference 
between dipyridamole treatment and vehicle control (P   0.025). (b) To assess 
vascular barrier function, animals were administered intravenous Evan’s blue 
solution (0.2 ml of 0.5% in PBS) before normoxia/hypoxia exposure. Animals 
were killed and indicated organs were harvested. Evan’s blue concentrations 
were quantified as described in Materials and methods. Data are expressed 
as mean   SD Evan’s blue OD/50 mg wet tissue and are pooled from four to 
six animals per condition. *, differences between NBTI/vehicle treatment groups 
(P   0.025); #, differences between normoxia/hypoxia exposure (P   0.05). 
(c) Organ assessment of PMN accumulation by MPO measurements in the 
indicated organs after 4 h of normoxia/hypoxia exposure (*P   0.025 
compared with vehicle; #P   0.025 compared with normoxia).
Figure 10. ENT1 expression patterns in conditional Hif1  mutant 
tissue. Real-time PCR analysis of murine epithelial ENT1 transcript in 
conditional Hif1  mutant and littermate control animals subjected to 
normoxia or hypoxia. Data were calculated relative to  -actin and are 
expressed as relative ENT1 mRNA   SD, where transcript levels in control 
animals were normalized to 1. Results are derived from three animals in 
each condition.JEM VOL. 202, December 5, 2005 1501
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tent with the aforementioned results with dipyridamole, we
found decreased MPO activity in all organs of NBTI-treated
animals after hypoxia exposure (P    0.05 for all organs).
These in vivo results suggest that inhibition of ENT1 con-
tributes to the in vivo resuscitation of vascular leak syndrome
by nucleoside transport inhibitors.
Role of HIF in epithelial ENT1 expression in vivo
We extended these findings of HIF-1–mediated repression
of ENT1 expression into a genetic in vivo model. Here, we
examined baseline expression and the influence of hypoxia
on mENT1 mRNA levels in intestinal epithelia derived
from conditional Hif1  knockout mice, in which intestinal
epithelia from these mice lack detectable Hif1  expression
in  70% of cells (3). As shown in Fig. 10, ENT1 levels in
mice expressing wild-type Hif1  showed a normal pattern
of hypoxia-associated ENT repression (68   3% decrease af-
ter hypoxia for 6, P   0.025). Consistent with our hypothe-
sis that HIF-1 transcriptionally represses ENT1, real-time
PCR analysis revealed a 37   6.8-fold increase in intestinal
epithelial ENT1 expression in Hif1  mutant animals (Fig.
10), relative to their littermate controls (P   0.01). Exposure
of HIF1  mutants to hypoxia decreased ENT1 expression
(P   0.05), but to a far lesser extent than in wild-type ani-
mals. These latter findings likely reflect the remaining  30%
wild-type Hif1  expression in these mice (3). Together, such
findings support our in vitro findings and indicate the likeli-
hood that HIF-1 directly regulates murine ENT1 expression.
DISCUSSION
Ado exerts paracrine and autocrine functions on most cell
types. Pathophysiologic conditions of hypoxia/ischemia re-
sult in numerous adenine nucleotide metabolic changes, and
targets for extracellular Ado signaling is now an area of much
interest. In the present studies, we explored the mechanisms
of extracellular Ado accumulation during hypoxia. For these
studies, we used vascular endothelial and mucosal epithelial
cells, which both lie anatomically positioned to function as
determinants of the inflammatory response. Our results re-
vealed that hypoxia increases extracellular Ado half-life. This
response is mechanistically determined, at least in part, by
HIF-1–regulated ENT1 repression.
The results from the present study are consistent with
previous findings that hypoxia inhibits intracellular metabo-
lism of Ado to AMP. Decking et al. showed, by measuring
Ado and AMP concentrations in the coronary sinus and cor-
onary arteries of isolated guinea pig hearts, that hypoxia is as-
sociated with a functional inhibition of the Ado kinase (30).
The authors propose that hypoxia-associated inhibition of
the Ado kinase leads to increased intracellular Ado levels. It
is known that during hypoxia, Ado flux is predominantly di-
rected from the extracellular to the intracellular space (14).
Therefore, two cellular strategies with regard to Ado trans-
port may play a role to elevate extracellular Ado levels dur-
ing hypoxia. First, as described by Decking et al., increased
intracellular Ado levels due to inhibition of Ado kinase–
dependent metabolism of Ado to AMP would decrease the
transcellular Ado gradient, thereby decreasing flux through
bidirectional ENTs and, thus, elevating extracellular Ado
levels during hypoxia (30). Second, transcriptional repression
of ENTs, as we demonstrate in the present work, decreases
overall equilibrative Ado transport capacities, thereby de-
creasing intracellularly directed Ado transport. It should be
noted that we have not observed a direct change in ENT
function by hypoxia per se. Rather, our studies addressed
function as it related to expression levels of ENT. From this
standpoint, it is likely that inhibition of adenine nucleotide
metabolism (e.g., inhibition of Ado kinase) could serve as an
immediate response to hypoxia (within minutes), whereas
our proposed transcriptional mechanism serves as a more
adaptive phenotype (within hours). Therefore it is reason-
able that both mechanisms could function during hypoxia
and, from this perspective, contribute synergistically to elevate
extracellular Ado during hypoxia.
Consistent with recent work in cardiac myocytes (16),
the present studies in vascular endothelia and mucosal epi-
thelia identified transcriptional repression of ENT as a
mechanism for such decreased Ado uptake during hypoxia.
Given the temporal and robust hypoxia response observed
in the repression of ENT1, a candidate regulator was HIF-1,
a heterodimeric transcription factor whose activation is de-
pendent on stabilization of an O2-dependent degradation
domain (31). It is recently appreciated that HIF can func-
tion as both a transcriptional activator as well as a repressor
(19). Therefore, a search of the cloned ENT1 gene pro-
moter identified two potential HIF-1–binding DNA con-
sensus motifs located in the distal 5  region of the ENT1
promoter. However, the existence of a HIF-1 –binding
consensus is not evidence for HIF-1 –mediated response;
instead, the HRE is defined as a cis-acting transcriptional
regulatory sequence located within 5 -flanking, 3 -flank-
ing, or intervening sequences of target genes (32, 33).
Therefore, two strategies were used to define the role of
HIF-1 in repression of ENT1. First, mutational analysis of
ENT1 promoter constructs defined a functional HRE lo-
cated in the distal 5 region of the ENT1 promoter ( 717
to  721 relative to the major transcription start site). Sec-
ond, ChIP analysis confirmed HIF-1  binding to the
ENT1 promoter. At present, we do not know if this bind-
ing is direct or indirect, and we do not know the nature of
HIF-mediated transcription. While previous work with
peroxisome proliferator-activated receptor   (PPAR- )
gene implicated potential repressor activity with HIF-1 
binding sites oriented on the antisense strand (20), implying
some degree of transcriptional directionality, there is not
direct evidence for such a mechanism. Moreover, while a
recent study comparing transcriptional responses between
hypoxia and constitutively active HIF1-1  identified a
large cohort of transcriptionally repressed genes (19), no
unique patterns of HRE expression were noted. Thus,
more work will be necessary to define the nature of HIF-
mediated repression.HIF-1–DEPENDENT REPRESSION OF ENT | Eltzschig et al. 1502
The present study also identified ENT1 as a potential
physiologic target in vivo. Indeed, using the ENT inhibitor
dipyridamole, we demonstrated that blockade of ENT1 pre-
vents vascular leakage associated with hypoxia, presumably
through accumulation of vascular Ado. Several lines of evi-
dence support the presumption that elevated Ado attenuates
vascular leakage. First, Nozik-Grayck determined that dipy-
ridamole effectively attenuates edema in an isolated perfused
lung model of hyperoxia (34). Second, in murine models of
hypoxia, decreased vascular Ado is associated with substan-
tially increased vascular leakage (8, 10, 22). In particular,
these observations have been made in animals lacking the
ability to metabolize adenine nucleotide precursors into
Ado, including cd39 and cd73-null animals (8, 10, 22).
Third, the administration of Ado analogues in the form of
Ado receptor A2a or A2b agonists, as well as the nonspecific
analogue 5 -(N-ethylcarboxamido)-Ado (NECA), protect
the vasculature during hypoxia-induced leakage (10). This
hypothesis was also tested in a conditional Hif1  mutant
mice, a mouse line that has revealed a protective role for
murine HIF-1  in a mucosal inflammation model (3). Using
this same mouse line, we confirmed our hypothesis that HIF
transcriptionally represses ENT1. Indeed, our findings re-
vealed that colonic epithelial cells lacking Hif1  express in-
creased ENT1 transcript. Of particular interest, analysis of un-
manipulated  Hif1  mutant mice (i.e., normoxia condition)
revealed substantial increases in ENT1. Such findings suggest,
as previously speculated (3, 9), that HIF may regulate homeo-
static gene expression (i.e., “physiologic hypoxia”) in tissues
with normally low pO2 values (e.g., colon) (35).
These results identify ENT repression as a mechanism for
attenuating both inflammatory responses and vascular leakage
during hypoxia. Interaction of HIF-1 with the ENT1 pro-
moter region is central to the observed inhibition of ENT1
gene expression. Extensions of these findings will determine
whether ENT regulation via HIF-1 might function as a path-
way for development of therapies for disorders involving
vascular leak syndromes or excessive inflammatory responses.
MATERIALS AND METHODS
Cell culture. HMEC-1 were a gift from F. Candal (Centers for Disease
Control, Atlanta, GA) (36) and were cultured as described previously (37).
For preparation of experimental HMEC-1 monolayers, confluent endothe-
lial cells were seeded at  105 cells/cm2 onto either permeable polycarbon-
ate inserts or 100 mm Petri dishes. Endothelial cell purity was assessed by
phase microscopic “cobblestone” appearance and uptake of fluorescent
acetylated low-density lipoprotein. Where indicated, T84 cells were cultured
as described previously (9, 38).
Measurement of Ado in supernatants. HMEC-1 were grown to full
confluency and exposed as indicated to normoxia or different degrees of hyp-
oxia. To develop a model for kinetics of endothelial Ado uptake, we first
measured Ado uptake in the supernatant of HMEC-1 monolayers with dif-
ferent Ado concentrations (1–500  M) and found optimal resolution of Ado
uptake when using 50  M Ado concentrations. These conditions were used
throughout for further measurements. After washing in HBSS and addition
of 50  M Ado, samples from the supernatant were collected at indicated
time points, and Ado concentrations were resolved by HPLC with a pump
P680 and an UVD 170 detector on a reverse-phase column (Grom-Sil 120-
ODS-ST-5 ; 150   3 mm Grom) using a mobile phase gradient from 0 to
25% acetonitrile/0.3 mM KH2PO4 (pH 5) in 5 min. Ultraviolet absorption
spectra were measured at 260 nm with a retention time for Ado of 2.8 min.
Measurement of Ado uptake. HMEC-1 were grown to full confluency
and exposed as indicated to normoxia or hypoxia. To measure endothelial
Ado uptake, 10 nCi of 8-14C-Ado (Sigma-Aldrich) was added to the super-
natant, in addition to a 50  M concentration of “cold” Ado. After indicated
time periods, cells were washed with HBSS and lysed in cold H2O. Assess-
ment of intracellular Ado uptake was done by measuring the radioactivity
within the lysates by directly diluting the lysate into the scintillation mix-
ture (Ultima Gold HFL-LSC-Cocktail; Packard) and counting decays per
minute (Liquid Scintillation Counter Packard 1600).
Transcriptional analysis. Conventional PCR was used to verify endo-
thelial ENT1 and ENT2 mRNA regulation, as described previously (38).
The PCR reaction contained 1  M each of the sense primer 5 -AAG-
GCACCTGGTTTCTGTC-3  and the antisense primer 5 -CTTGGGCT-
TGGAGAACAC-3  for ENT1, and 5 -CTTCCATACCCACTCTCT-
CACC-3  and 5 -GAGAGAGAGGGGATTGGGTC-3  for ENT2,
respectively. The primer set was amplified using increasing numbers of cy-
cles of 94 C for 1 min, 58 C for 2 min, 72 C for 4 min, and a final exten-
sion of 72 C for 7 min. The PCR transcripts were visualized on a 1.5% aga-
rose gel containing 5  g/ml of ethidium bromide. Human  -actin (sense
primer, 5 -TGACGGGGTCACCCACACTGTGCCCATCTA-3  and
antisense primer, 5 -CTAGAAGCATTTGCGGTGGACGATGGAGGG-3 )
in identical reactions was used to control for the starting template.
In subsets of experiments, the transcriptional profile of endothelial cells
subjected to normobaric hypoxia (12 h) was compared in RNA derived
from control or hypoxic endothelia using quantitative genechip expression
arrays (Affymetrix, Inc.) as described before (9). Where indicated, mRNA
was also quantified by real-time PCR (iCycler; Bio-Rad Laboratories Inc.)
as described previously (9). The primer sets contained 1  M sense and 1
 M antisense containing SYBR green I (GE Healthcare) in the reaction
mixture. Transcript levels and fold change in mRNA were determined as
described previously (39). In addition, real-time PCR was performed from
RNA isolations of human saphenous vein after ex vivo exposure to hyp-
oxia. After approval by the institutional review board, saphenous vein ma-
terial was obtained from patients undergoing aorta-coronary bypass surgery.
Equal portions of dissected vein tissue were subjected to hypoxia (pO2 20
torr) immediately after the operation for different time points (0, 2, 8, and
24 h). After hypoxia exposure, total RNA was isolated from the tissues and
real-time PCR was performed as described before.
Macromolecule paracellular permeability assay. Using a modifica-
tion of methods previously described (18), HMEC-1 were grown on poly-
carbonate permeable supports (0.4- m pore, 6.5-mm diam; Costar Corp.)
and studied 7–10 d after seeding (2–5 d after confluency). Inserts were
placed in HBSS-containing wells (0.9 ml), and HBSS (alone or with indi-
cated concentrations of Ado, with and without 10  M concentration of
dipyridamole) was added to inserts (100  l). At the start of the assay (t   0),
FITC-labeled dextran 70 kD (concentration 3.5  M) was added to fluid
within the insert. The size of FITC-dextran, 70 kD, approximates that of
human albumin, both of which have been used in similar endothelial para-
cellular permeability models (18). Fluid from opposing well (reservoir) was
sampled (50  l) over 60 min (t   20, 40, and 60 min). Fluorescence inten-
sity of each sample was measured (excitation, 485 nm; emission, 530 nm;
Cytofluor 2300; Millipore Corp., Waters Chromatography) and FITC-dex-
tran concentrations were determined from standard curves generated by se-
rial dilution of FITC-dextran. Paracellular flux was calculated by linear
regression of sample fluorescence.
Immunoblotting experiments. HMEC-1 were grown to confluency on
100-mm dishes and exposed to indicated experimental conditions. TheJEM VOL. 202, December 5, 2005 1503
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monolayers were lysed for 10 min in 300  l lysis buffer (150 mM NaCl, 25
mM Tris, pH 8.0, 5 mM EDTA, 2% Triton X-100, and 10% mammalian
tissue protease inhibitor cocktail; Sigma-Aldrich), scraped and collected into
microfuge tubes. After spinning at 14,000 g to remove cell debris, the pellet
was discarded. Proteins were solublized in nonreducing Laemmli sample
buffer and heated to 90 C for 5 min. Samples were resolved on a 12% poly-
acrylamide gel and transferred to nitrocellulose membranes. The membranes
were blocked for 1 h at room temperature in PBS supplemented with 0.2%
Tween 20 (PBS-T) and 4% BSA. The membranes were incubated in 5  g/
ml polyclonal rabbit anti-ENT1 in PBS-T for 1 h at room temperature, fol-
lowed by 10 min washes in PBS-T. The membranes were incubated in
1:3,000 goat anti–rabbit IgG (ICN Biomedicals/Cappel), and conjugated to
horseradish peroxidase for 1 h at room temperature. The wash was repeated
and proteins were detected by enhanced chemiluminescence. To control for
protein loading, blots were stripped and reprobed for  -actin using a mouse
monoclonal anti–human  -actin antibody (Abcam Inc.). In subsets of exper-
iments, identical conditions were used to examine HIF-1  protein levels in
nuclear lysates derived from HMEC-1. For these purposes, 1  g/ml of
monoclonal mouse anti–HIF-1  (Novus Biologicals) was used.
ENT1 and ENT2 suppression with RNA interference.  HMEC-1
were either grown on inserts or in 60-mm Petri dishes. Different sets of
siRNA directed against human ENT1 and ENT2 were designed using stan-
dard molecular tools, synthesized by Dharmacon, and tested with RT-PCR
for their efficiency to suppress ENT1 and ENT2 expression at different
concentrations. Highest efficiencies were found with 5 -CGGCCACU-
CAGUAUUUCACdTdT-3  (sense strand) and 5 -GUGAAAUACUGA-
GUGGCCGdTdT-3  (antisense strand) for ENT1 and 5 -CUCUCU-
CACCGAAGCCUAAdTdT-3  (sense strand) and 5 -UUAGGCUUCG-
GUGAGAGAGdTdT-3  (antisense strand) for ENT2. As nonspecific control,
the sense strand of the ENT2 oligoribonucleotide was used under identical
conditions. As additional control, knockdown with a set of siRNA directed
against human 5 -ectonucleotidase (CD73) was performed using the sense
sequence 5 -CUAUCUGGUUCACCGUGUAdTdT-3  (sense strand) and
5 -UACACGGUGAACCAGAUAGdTdT-3  (antisense strand). HMEC-1
loading was accomplished using standard conditions of Fugene6 (Roche
Diagnostics Corp.), when cells had reached 40–60% confluence. After 48 h
of loading, RNA was isolated as described before or functional assays (flux
assays, Ado uptake) were performed.
ENT1 reporter assays. Plasmids expressing sequence corresponding to
full-length ENT1 ( 756 to  1), or the following 5  truncations: ENT1-
344 (bp  334 to  1), ENT1-282 (bp  282 to  1), ENT1-225 (bp  225
to  1), have been previously characterized (unpublished data). As a control
for hypoxia, cells were transfected with a PGL3-based HRE plasmid con-
taining four tandem HIF-1 enhancer sequences from the 3 -region of the
erythropoietin gene (40). HMEC-1 were cotransfected with constitutively
expressed Renilla plasmids using standard methods of overnight transfection
using polyfect transfection reagent (QIAGEN). T84 cells were transfected
using solution T and a modified form of electroporation (Amaxa Inc.). After
transfection, cells were subjected to hypoxia or normoxia for 48 h. Lu-
ciferase activity was assessed (Turner Designs) using a luciferase assay kit
(Promega). All firefly luciferase activity was normalized with respect to the
constitutively expressed Renilla luciferase reporter gene.
In subsets of experiments, HIF-1–binding site mutations were introduced
in ENT1-756 plasmids using the GeneEditor in vitro site-directed mutagene-
sis system (Promega). In brief, mutations encoding two nucleotide mutations
ENT1 HIF-1 binding sites at positions  721 and  657, respectively, as de-
scribed previously. All mutations were confirmed by sequencing using pGL3-
basic primers. Hypoxia inducibility in transient transfectants using such mu-
tated luciferase constructs was exactly as described in the previous paragraph.
ChIP assay. ChIP assays were performed using HMEC-1 subjected to
normoxia or hypoxia. In brief, 2   107 cells were fixed with 1% parafor-
maldehyde for 10 min. Cross-linking was stopped by the addition of 125 mM
glycine, and chromatin derived from isolated nuclei was sheared using a
F550 micro-tip cell sonicator (Fisher Scientific). After centrifugation, super-
natants containing sheared chromatin were incubated for 4 h with 5  g
of anti–HIF-1  antibody (Novus Biologics) or control IgG. Protein A
sepharose was added and the incubation continued overnight at 4 C. Im-
mune complexes were washed extensively and eluted from the protein A
sepharose. The supernatants were transferred to a new tube, and 1  g/ l of
RNase was added and incubated for 5 h at 67 C. Samples were frozen at
 80 C and 60  g/ l proteinase K was added and incubated for 2 h at
45 C. Next, samples were diluted with TE containing 10  g of tRNA fol-
lowed by one extraction with phenol/chloroform and one extraction with
chloroform. DNA was precipitated from the samples, washed, dried, and
resuspended in 30  l of autoclaved water. 2  l of sample was used for each
PCR reaction. The sequences of the ENT1 promoter-specific primers
spanning the putative HIF-1–binding region were as follows: sense, 5 -GTG-
TCAGTGCACATCTGCCTGGC-3  and antisense, 5 -CCTGTCCG-
CTTCCCCTTTCTAAG-3 . The size of the amplified product resulting
from the use of this primer pair was 192 bp.
Lentiviral vector design, production, and transduction in T84
cells.  The HIV-1 lentiviral vector used was based on a vector previously
described in detail (41). In short, the  ODD variant of HIF-1  (containing
a proline→alanine substitution at position 564; the ODD mutant HIF-1 
plasmid was provided by H. Franklin Bunn [Harvard Medical School, Bos-
ton, MA]) (21) was cloned into the Bam HI/ClaI sites of the lentiviral
vector. Virus was produced by first transfecting 293T cells with 3.2  g of vec-
tor, 4.0  g of the packaging plasmid, and 0.4  g of REV, TAT, and VSV-G
and collecting and filtering the cell supernatant through a 0.45- m filter.
Viral titers were determined by FACS analysis and/or quantitative Southern
blot analysis. T84 cells were plated at a density of 2   105 cells/10cm2 dish
24 h before transduction. These cells were transduced using 2   106 infec-
tious U/ml (MOI   10) of viral supernatant along with 5  g/ml protamine
sulfate for 3 h at 37 C. Cells were fed and propagated in standard T84 media.
In vivo hypoxia model.  C57BL/6/129 svj mice were matched accord-
ing to sex, age, and weight. Total organ vascular permeability was quanti-
fied by intravascular administration of Evan’s blue as described previously
(42). Animals were injected with dipyridamole (10 mg/kg i.p. and 10 mg/
kg s.c) or of S-(4-nitrobenzyl)-6-thioinosine (NBTI, 1 mg/kg i.p.[Sigma-
Aldrich]) or vehicle (DMSO). For the purpose of quantifying vascular per-
meability, 0.2 c.c. of Evan’s blue (0.5% in PBS) were injected intravenously.
Animals were exposed to normobaric hypoxia (8% O2, 92% N2) or room
temperature air for 4 h (n   6 animals per condition). After hypoxia/nor-
moxia exposure, the animals were killed and the colon, kidney, liver, and
lungs were harvested. Organ Evan’s blue concentrations were quantified af-
ter formamide extraction (55 C for 2 h) by measuring absorbances at 610
nm with subtraction of reference absorbance at 450 nm. Pulmonary edema
was assessed in additional experiments. For this purpose, lungs of the ani-
mals (n   6) were collected, weighed, and dried by speed-vac (Eppendorf
Vacufuge). Weight differences before and after drying were used to calcu-
late lung water content. For the purpose of quantifying PMN tissue con-
centrations, the animals were exposed to normobaric hypoxia (8% O2, 92%
N2) or room temperature air for 4 h (n   4–6 animals per condition). After
hypoxia/normoxia exposure, the animals were killed, organs were har-
vested, and the PMN marker MPO was quantified as previously described
(43). Plasma levels of dipyridamole were determined by HPLC with a
pump P680 and a Hitachi Fluorescence Detector L-7480 on a reverse-phase
column (Grom-Sil 120-ODS-ST-5 ; 150   3 mm Grom) using a mobile
phase gradient from 0 to 33% acetonitrile/0.3 mM KH2PO4 (pH 5) in 10
min. Fluorescence was measured at 404 nm excitation and 480 nm emission
wavelength, with a retention time for dipyridamole of 8 min.
In subsets of experiments, colonic mucosal scrapings (enriched in epi-
thelial cells) were obtained from 6–8-wk-old conditional Hif1  mutant
mice or littermate controls, as described before (3). Scrapings were homog-
enized in RNAlater (QIAGEN) using a 22-gauge syringe (Becton Dickin-HIF-1–DEPENDENT REPRESSION OF ENT | Eltzschig et al. 1504
son) and Qiashredder column (QIAGEN). RNA extraction including
DNase digestion was performed using the RNeasy kit (QIAGEN). Re-
verse-transcription was done using the iScript cDNA Synthesis Kit (BioRad
Laboratories). Amplification was performed on an i-Cycler IQ real-time
PCR detection system (BioRad Laboratories) using the gene-specific prim-
ers for ENT1 as described before. These protocols were in accordance with
National Institutes of Health guidelines for use of live animals and were ap-
proved by the Institutional Animal Care and Use Committee at Brigham
and Women’s Hospital.
Data analysis.  Data were compared by two-factor analysis of variance, or
by Student’s t test where appropriate. Values are expressed as the mean  
SD from at least three separate experiments.
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